Wednesday, September 22 2021 11:20

ArmInfo. The Russian Direct Investment Fund (RDIF, the sovereign fund of the Russian Federation), the Ministry of Economy of the Republic of Armenia and  the leading pharmaceutical company in Armenia, Liqvor  Pharmaceuticals, announce the production of the first batches of  Sputnik Light, a single-component Russian vaccine against  coronavirus. This was reported by the press service of the RDIF.  Sputnik Light is the first component (recombinant human adenovirus 26  serotype (rAd26)) of the Sputnik V vaccine. The drug, produced in  Armenia, will be used to vaccinate the population against the  coronavirus.

RDIF organized a technological transfer process for vaccine  production in Armenia at the facilities of the Liqvor company. The  validation lots of Sputnik Light will be sent to the N.N. N.F.  Gamalea for quality control, the successful completion of which will  allow you to start commercial production.

"Sputnik Light" was approved for use in Armenia on September 6 this  year. In February 2021, the country also approved the use of the  Sputnik V two-component vaccine.

Sputnik Light demonstrates high safety and efficiency in vaccination  of the population in a number of countries. In particular, data from  the Ministry of Health of the province of Buenos Aires (Argentina)  showed the effectiveness of the Sputnik Light vaccine at the level of  78.6-83.7% when vaccinating the elderly. In Paraguay, according to  the country's Ministry of Health, the effectiveness of the drug was  93.5% during mass vaccination.

Due to its high safety and efficacy in a number of countries, the  Sputnik Light vaccine is currently used not only independently, but  is also being studied in combination with drugs from other  manufacturers. Similar research is currently underway in Argentina,  the UAE and other countries.

Minister of Economy of Armenia Vahan Kerobyan stated: "Sputnik Light  vaccine production jointly with RDIF and Liqvor company in Armenia,  is an important step in the development of the pharmaceutical  industry in our country. I must note that this is a good example of  cooperation between the two countries in the fight against the  coronavirus pandemic and overcoming its socio-economic consequences.  "

In turn, Director General of the Russian Direct Investment Fund,  Kirill Dmitriev, in particular, noted:  "Establishing the production  of a Sputnik Light single-component vaccine, which demonstrates  higher efficiency than many two-component drugs against coronavirus,  is an important stage in cooperation between Russia and Armenia in  the fight with a pandemic. Local production of the Sputnik Light  vaccine will accelerate the vaccination of the population, avoid  logistics costs and quickly form herd immunity. " Key benefits of the  Sputnik Light vaccine:

Sputnik Light is the first component (recombinant human adenovirus 26  serotype (rAd26)) of the Sputnik V vaccine, the world's first  registered vaccine against coronavirus.  According to the results of  laboratory studies of the N.N. N.F. Gamalei, "Sputnik Light" is  effective against new strains of coronavirus.

Sputnik Light does not require special storage and logistics  conditions.

The Sputnik Light vaccine is created on the studied and tested  platform of human adenoviral vectors, the important advantages of  which are safety, efficacy and the absence of long-term negative  consequences, confirmed in more than 250 clinical studies conducted  in the world over two decades (with the history of the use of  adenoviruses human vaccines began in 1953).